OTC sunscreens rule
This article was originally published in The Tan Sheet
Executive Summary
FDA will continue to accept comments on its proposed rule to amend the final monograph for over-the-counter sunscreen products until Dec. 26, the agency announces in a Nov. 28 Federal Register notice. The agency pushed the deadline back by one month in response to requests from parties wanting additional time to submit comments. FDA issued the proposed rule Aug. 23, amending the final monograph to include UVA ray protection standards including in vivo and in vitro tests (1"The Tan Sheet" Aug. 27, 2007, p. 3). The final monograph was issued in 1999, but has consistently been stayed due to pressure from industry...
You may also be interested in...
Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity
FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers (see chart: "1Selected Proposed Changes To OTC Sunscreen Monograph")
EMA's Decision On Ranitidine Remaining Available Could Come At End Of April
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: